Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
SURMOUNT-1 results for each Mounjaro dose: weight loss, side effects and what it means for you.

Mounjaro (tirzepatide) has three maintenance doses: 5, 10 and 15 mg. Many patients assume the goal is to reach 15 mg. The data from the main trial paint a more nuanced picture, though: there is a difference between doses, but it is smaller than you might think, especially between 10 and 15 mg.
In short: in the SURMOUNT-1 trial, after 72 weeks, average weight loss was −15.0% on 5 mg, −19.5% on 10 mg and −20.9% on 15 mg. Almost all patients lost at least 5%, regardless of dose (85–91%). The right dose is decided with your doctor, based on your results and how well you tolerate treatment.
How the Mounjaro dose is increased
According to the European prescribing information (SmPC), treatment starts at 2.5 mg once a week for 4 weeks. The 2.5 mg dose is only for initiation, to let your body adjust. The dose is then increased to 5 mg. If needed, the doctor can increase it in 2.5 mg steps, with at least 4 weeks between steps. The recommended maintenance doses are 5, 10 and 15 mg, and the maximum dose is 15 mg.
This means that staying on 5 mg or 10 mg is an option provided for in the prescribing information, not a deviation. The same logic applies to other drugs in the class, as we explain in our article on the minimum effective dose. You can see the dose-escalation schedule in the Mounjaro calculator.
The SURMOUNT-1 trial: results for each dose
SURMOUNT-1 is the trial on which tirzepatide was approved for obesity. It was published in the New England Journal of Medicine in 2022.
Who took part: 2,539 adults with obesity (or overweight with at least one weight-related complication), without diabetes. Average starting weight was 104.8 kg. All participants also received counseling on diet and physical activity.
How it was done: participants were randomly assigned to 5 mg, 10 mg, 15 mg or placebo for 72 weeks, of which the first 20 weeks were a gradual dose escalation. Neither patients nor doctors knew who was receiving what (a double-blind trial).
Results
| 5 mg | 10 mg | 15 mg | Placebo | |
|---|---|---|---|---|
| Average weight loss | −15.0% | −19.5% | −20.9% | −3.1% |
| Lost at least 5% | 85% | 89% | 91% | 35% |
| Lost at least 20% | – | 50% | 57% | 3% |
| Stopped treatment because of side effects | 4.3% | 7.1% | 6.2% | 2.6% |
The share of participants who lost at least 20% is reported in the trial abstract only for the 10 and 15 mg doses.
What these numbers mean
1. The biggest jump is between 5 and 10 mg. Going from 5 to 10 mg added 4.5 percentage points on average. From 10 to 15 mg, only 1.4 points.
2. Almost everyone responds, even on 5 mg. 85% of patients on 5 mg lost at least 5%, a loss considered medically meaningful. On 15 mg, the share was 91%.
3. Side effects do not rise in a straight line. Most were gastrointestinal (nausea, diarrhea, constipation; see how to manage them), mild or moderate, and occurred mainly during dose escalation. The share of people who quit because of them was lower on 5 mg (4.3%) than on the higher doses (6–7%).
4. Averages hide variation. On the same dose, some patients lose far more than average, others far less. The numbers in the table don't tell you how much you will lose, only what happened on average in a large group.
How the doctor chooses the dose
Doctors usually take into account:
- how much you have lost so far on your current dose and whether you are still losing;
- how you tolerate treatment: persistent side effects are a legitimate reason not to increase the dose;
- the goal: active weight loss or maintenance;
- other conditions: for example, diabetes can change the goal of treatment.
- cost: different doses can be priced differently.
If you are losing weight steadily on 5 mg and tolerating treatment well, there is no rule that requires increasing the dose simply because a higher one exists.
To follow how you respond at each step, a Mounjaro tracker app such as Reko (partner app, iPhone) logs every dose, injection site and side effect next to your weight.
Conclusion
The SURMOUNT-1 data show that Mounjaro 5 mg has a real and meaningful effect, and that the difference between 10 and 15 mg is small on average. The maximum dose brings the largest average effect, but it is not mandatory for everyone. If you are considering a lower dose, avoid the "microdoses" sold online. Talk to your doctor about which dose fits your goals and how you respond to treatment. For the phase after weight loss, see what the trial on dose reduction shows.
Frequently asked questions
What is the difference in weight loss between Mounjaro 5 mg and 15 mg? In SURMOUNT-1, after 72 weeks: −15.0% on 5 mg versus −20.9% on 15 mg, an average difference of about 6 percentage points.
Is it worth going from 10 to 15 mg? On average, the difference was small: −19.5% versus −20.9%. For some patients it may matter; for others it does not justify the side effects. It is a decision to make with your doctor.
Is 2.5 mg a treatment dose? No. According to the prescribing information, 2.5 mg is the starting dose, used for the first 4 weeks.
Are side effects less common on 5 mg? In SURMOUNT-1, fewer patients stopped treatment because of side effects on 5 mg (4.3%) than on 10 mg (7.1%) or 15 mg (6.2%).
Can I stay on 5 mg long term? The European prescribing information lists 5 mg among the recommended maintenance doses. The length of treatment and the dose are decided with your doctor.
Read also
Useful calculators
- Mounjaro calculator: the dose-escalation schedule and SURMOUNT-1 results for each dose.
- BMI calculator: find your body mass index, one of the eligibility criteria.
The "GLP-1 dose" series
- The minimum effective GLP-1 dose: do you need the maximum dose?
- Mounjaro 5 mg vs 10 mg vs 15 mg: what the trials show
- Lowering the dose after weight loss: the SURMOUNT-MAINTAIN trial
- GLP-1 microdosing: what's real and what's marketing
- Ozempic overdose: why you shouldn't calculate your own dose
- Reducing your GLP-1 dose: how to talk to your doctor
Sources
- Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. doi:10.1056/NEJMoa2206038
- Mounjaro Summary of Product Characteristics (SmPC), European Medicines Agency.
Educational content, updated September 2026. It does not replace medical advice. Do not change the dose, frequency or way you take a medicine without the agreement of the doctor who prescribed it.
This article is for general information only and does not replace advice from your doctor or pharmacist. Do not start, stop or change a treatment without medical supervision.


